DR.ASHISH SHARMA (S13838)

Abstract

BIOLOGICS SINCE THEIR INCEPTION HAVE REVOLUTIONISED THE TREATMENT PROTOCOL BY DIRECTLY TARGETING THE MOLECULAR PATHOPHYSIOLOGY OF MANY DISEASES. BUT THEIR DEVELOPMENT WAS RESTRICTED DUE TO A DEMANDING R&D PROCESS MAKING THEM COSTLY THERAPY. WITH DEVELOPMENT OF BIOSIMILARS, THE BIOLOGICS WHICH ARE SIMILAR IN STRUCTURE, EFFICACY, AND SAFETY TO THE REFERENCE MOLECULES, ARE WELL REGULATED; THE COST OF TREATMENT HAS REDUCED UP TO 25%. SENSING THE LARGE BUSINESS OPPORTUNITY, THERE IS A WAVE OF BIOSIMILARS BEING LAUNCHED GLOBALLY FOR RETINAL DISEASES. INDIA WITH ITS VAST EXPERIENCE WITH EARLY ADOPTION CAN BECOME THE LEADERS IN THE SEGMENT. THE COURSE AIMS TO PROVIDE AN OVERVIEW OF BIOSIMILARS, THEIR REGULATIONS AND DRUG TRIALS, SAFETY, EFFICACY, FINANCIAL IMPLICATIONS, FUTURE PROSPECTS AND BIOBETTERS IN FORM OF DIDACTIC LECTURES. THE COURSE DEDICATES TIME FOR PANEL DISCUSSION AND AUDIENCE INTERACTION FOR A BETTER UNDERSTANDING OF THE SUBJECT.

1	INTRODUCTION TO THE COURSE (5 mins)	Dr.ASHISH SHARMA	watch video
2	BIOLOGICS, BIOSIMILARS AND BIOBETTER- WHAT DO THEY MEAN (9 mins)	DR. NILESH KUMAR	watch video
3	UNDERSTANDING THE REGULATORY AND DRUG TRIAL DESIGN OF BIOSIMILARS (9 mins)	Dr.ASHISH SHARMA	watch video
4	ON-LABEL BEVACIZUMAB- AN ORIGINATOR OR A BIOSIMILAR? (5 mins)	Dr.NIKULAA PARACHURI	watch video
5	BIOSIMILARS- LESSONS TO BE LEARNT FROM INDIA (9 mins)	Dr. MANGAT R. DOGRA	watch video
6	THE FINANCIAL IMPLICATIONS OF BIOSIMILARS (9 mins)	Dr. SATYA PRAKASH TIWARY	watch video
7	THE REAL-WORLD EXPERIENCE OF BIOSIMILARS (9 mins)	Dr. DEBDULAL CHAKRABORTY	watch video
8	KEYNOTE ADDRESS BY : DR JAI SHANKAR : RETINAL VEIN OCCLUSION – (10 MINS)	DR. JAI SHANKAR	watch video
	Panel Discussion : (20 mins.)